NCT05083390View on ClinicalTrials.gov

Norursodeoxycholic Acid vs. Placebo in NASH

PHASE2RecruitingINTERVENTIONAL
Enrollment

363

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

January 31, 2025

Study Completion Date

April 30, 2025

Conditions
Nonalcoholic Steatohepatitis
Interventions
DRUG

norUrsodeoxycholic acid

500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day

Trial Locations (1)

Unknown

RECRUITING

Medical University of Vienna, Department of Internal Medicine III, Vienna

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY